Evonile Pharma (500672) Q4 24/25 earnings summary

Executive summary

• FY25 revenue from operations was INR3,350.7 million, down from INR3,562.7 million; profit for the year rose to INR1,009.0 million from INR851.9 million.

• The board recommended a final dividend of INR25 per share, subject to shareholder approval at the 77th AGM.

Financial highlights

• Q4 FY25 revenue from operations was INR838.8 million vs INR811.7 million in Q4 FY24; total income was INR945.1 million vs INR915.9 million.

• Q4 FY25 profit before tax was INR338.9 million vs INR213.3 million; profit for the period was INR293.0 million vs INR146.8 million.

• FY25 profit before tax was INR1,304.2 million vs INR1,228.4 million; total expenses were INR2,678.1 million vs INR2,739.1 million.

• FY25 total comprehensive income was INR1,018.7 million vs INR864.0 million in FY24.

Segment performance

• Operations comprise a single business segment, Pharmaceuticals Business.